DK1526840T3 - Nanopartikler til DNA administration til et målorgan - Google Patents

Nanopartikler til DNA administration til et målorgan

Info

Publication number
DK1526840T3
DK1526840T3 DK02767270T DK02767270T DK1526840T3 DK 1526840 T3 DK1526840 T3 DK 1526840T3 DK 02767270 T DK02767270 T DK 02767270T DK 02767270 T DK02767270 T DK 02767270T DK 1526840 T3 DK1526840 T3 DK 1526840T3
Authority
DK
Denmark
Prior art keywords
nanoparticles
target organ
dna administration
dna
administration
Prior art date
Application number
DK02767270T
Other languages
Danish (da)
English (en)
Inventor
Christian Walz
Bernhard A Sabel
Kerstin Ringe
Original Assignee
Nanodel Technologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanodel Technologies Gmbh filed Critical Nanodel Technologies Gmbh
Application granted granted Critical
Publication of DK1526840T3 publication Critical patent/DK1526840T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02767270T 2002-07-29 2002-07-29 Nanopartikler til DNA administration til et målorgan DK1526840T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/008434 WO2004017945A1 (en) 2002-07-29 2002-07-29 Nanoparticles for dna administration to a target organ

Publications (1)

Publication Number Publication Date
DK1526840T3 true DK1526840T3 (da) 2008-11-03

Family

ID=31896790

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02767270T DK1526840T3 (da) 2002-07-29 2002-07-29 Nanopartikler til DNA administration til et målorgan

Country Status (10)

Country Link
US (1) US7402573B2 (de)
EP (1) EP1526840B1 (de)
JP (1) JP2006500015A (de)
AT (1) ATE408398T1 (de)
AU (1) AU2002331356A1 (de)
CA (1) CA2492807A1 (de)
DE (1) DE60229003D1 (de)
DK (1) DK1526840T3 (de)
ES (1) ES2314097T3 (de)
WO (1) WO2004017945A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492807A1 (en) 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ
EP1661559A1 (de) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Verabreichungssystem hergestellt durch ein Miniemulsionsverfahren
ES2318531T3 (es) * 2004-09-14 2009-05-01 Nanodel Technologies Gmbh Vehiculo de administracion que contiene nanoparticulas.
WO2006056362A2 (en) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Delivery vehicle manufactured by the miniemulsion method
WO2006130943A1 (en) * 2005-06-10 2006-12-14 The Governors Of The University Of Alberta Respirable dried powder formulation comprising drug loaded nanoparticles
EP1815851A1 (de) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanopartikel zur Arzneistoffverabreichung
US20100196280A1 (en) * 2006-06-08 2010-08-05 Katrin Claudia Fischer Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications
JP4963221B2 (ja) * 2006-11-24 2012-06-27 公立大学法人横浜市立大学 シアノアクリレート系ポリマー粒子及びその製造方法
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
RU2617059C2 (ru) * 2014-11-11 2017-04-19 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения амфифильных блок-сополимеров N,N-диметиламиноэтилметакрилата для доставки нуклеиновых кислот в живые клетки
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
JP7203756B2 (ja) 2017-04-25 2023-01-13 イスケミックス エルエルシー 外傷性脳傷害を治療するための組成物および方法
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
HUE071524T2 (hu) 2018-07-03 2025-09-28 Gilead Sciences Inc HIV GP120-at célzó antitestek és alkalmazási eljárások
JP7490925B2 (ja) 2018-07-26 2024-05-28 エータイアー ファーマ， インコーポレイテッド Ｎｒｐ２関連疾患を治療するための組成物および方法
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4458975A3 (de) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv-impfstoffe und verfahren zur behandlung von hbv
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20250036855A (ko) 2022-07-12 2025-03-14 길리애드 사이언시즈, 인코포레이티드 Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
EP0840623B1 (de) * 1995-07-21 2007-07-18 Brown University Research Foundation Zusammensetzungen zur gentherapie die nukleinsäure-beladenen polymer-mikropartikeln enthalten
JP3778575B2 (ja) * 1997-06-13 2006-05-24 ナノデル テヒノロギーズ ゲーエムベーハー 薬剤標的化システム、その調製方法およびその使用
US6265546B1 (en) * 1997-12-22 2001-07-24 Genset Prostate cancer gene
EP1100475A1 (de) * 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Verwendung von arzneistoffbeladenen nanopartikel zur behandlung von krebs
CA2492807A1 (en) 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ

Also Published As

Publication number Publication date
US7402573B2 (en) 2008-07-22
DE60229003D1 (de) 2008-10-30
JP2006500015A (ja) 2006-01-05
ES2314097T3 (es) 2009-03-16
US20050175710A1 (en) 2005-08-11
AU2002331356A1 (en) 2004-03-11
EP1526840A1 (de) 2005-05-04
ATE408398T1 (de) 2008-10-15
CA2492807A1 (en) 2004-03-04
WO2004017945A1 (en) 2004-03-04
EP1526840B1 (de) 2008-09-17

Similar Documents

Publication Publication Date Title
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
EP2172549A3 (de) Rnai expressionskonstrukte
WO2007120811A3 (en) Hemangio-colony forming cells
ATE519777T1 (de) Magnetosomen-genexpression in eukaryotischen zellen
MX2007010996A (es) Nuevas composiciones de liposomas.
TW200716646A (en) (S)-N-methylnaltrexone
HUP0400371A2 (hu) Szén-monoxid alkalmazása szerv átültetés utáni túlélésének vagy működésének javítására alkalmas gyógyszerkészítmény előállítására
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
HRP20150828T1 (xx) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
CY1113424T1 (el) Μεθοδος αντιμετωπισης του καρκινου ή/και παθησεις με κυτταρικη υπερπλασια και παραγοντες που στοχευουν τον αναβολισμο υαλουρονανης για τον ιδιο σκοπο
WO2007005941A3 (en) Liver targeted conjugates
ATE514718T1 (de) Peptabody für krebsbehandlung
EP2407484A3 (de) Therapeutische proapoptotische BH3-ähnliche Moleküle und Verfahren zu deren Erzeugung und/oder Auswahl
WO2004094610A3 (en) Wnt as a factor for cardiac myogenesis
EP2386639A3 (de) Modifizierte porenformende Proteintoxine und Verwendung davon
SE0000597D0 (sv) Novel antibody
TW200724679A (en) Treatment of disease using an improved regulated expression system
DE60002603D1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
WO2006094076A3 (en) System and methods for preferentially enhancing activation of rac gtpase in a cell or tissue
WO2004087876A3 (en) Use of red blood cells to facilitate cell activation
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system